Not independent
Tenure on this board
5.5 yrs
6 nominees · 2 ballot items.
Proposal 1: Amend Articles to increase authorized common stock from 75,000,000 to 1,500,000,000; Proposal 2: Adjourn meeting to solicit additional proxies if necessary.
Amend Article IV to increase authorized common shares from 75,000,000 to 1,500,000,000 to provide flexibility for capital raises, employee benefit programs, conversion reserves, and acquisitions.
The proposal requests shareholder approval to amend Article IV of the Amended and Restated Articles of Incorporation to increase authorized common shares from 75,000,000 to 1,500,000,000. Management seeks this authority to provide flexibility for future capital raises (including in response to Nasdaq minimum bid-price non-compliance), to support employee benefit programs, to establish reserves for conversion of outstanding options/warrants/preferred stock and indebtedness, and to permit issuances in connection with acquisitions. The company states no definitive issuance plans exist but intends to consider private placements or public offerings to fund clinical trials for BRTX-100, preclinical ThermoStem work, biocosmeceuticals development, and general corporate purposes. Approval would allow the board broad discretion to issue shares without further shareholder approval unless required by law or listing rules, which raises dilution risk to current shareholders and potential use as an anti-takeover defense in the future. The timing and terms of any future issuances are unspecified, increasing investor uncertainty about dilution and price impact. The Board recommends a FOR vote, citing the need for flexibility to meet capital needs and potential Nasdaq compliance; the recommendation notes there are no current plans to entrench management but acknowledges possible future defensive uses. Given the company's Nasdaq non-compliance notice and significant outstanding convertible securities (roughly equal to the current authorized shares), shareholders should weigh the immediate need for listing-compliance options against the dilution risk and governance implications of authorizing a large increase in shares.
Authorize adjournment(s) of the meeting, if necessary, to solicit additional proxies to obtain sufficient votes to approve Proposal 1.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 0.94% | 238,606 | $65K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.86% | 219,852 | $60K |
| 3 | UBS Group AG | 0.39% | 99,832 | $27K |
| 4 | WEALTH ALLIANCE, LLC | 0.16% | 40,000 | $11K |
| 5 | VANGUARD FIDUCIARY TRUST CO | 0.15% | 39,452 | $11K |
| 6 | STATE STREET CORP | 0.13% | 32,459 | $9K |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 0.01% | 3,231 | $879 |
| 8 | OSAIC HOLDINGS, INC. | 0.01% | 2,000 | $540 |
| 9 | Tower Research Capital LLC (TRC | 0.01% | 1,462 | $398 |
| 10 | SBI Securities Co., Ltd. | 0.00% | 199 | $54 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.